Tandem Diabetes Care, Inc. Stock price

Equities

TNDM

US8753722037

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq 04:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
35.3 USD +4.73% Intraday chart for Tandem Diabetes Care, Inc. +8.75% +19.34%
Sales 2024 * 844M Sales 2025 * 936M Capitalization 2.32B
Net income 2024 * -110M Net income 2025 * -68M EV / Sales 2024 * 2.56 x
Net cash position 2024 * 156M Net cash position 2025 * 122M EV / Sales 2025 * 2.35 x
P/E ratio 2024 *
-21 x
P/E ratio 2025 *
-34 x
Employees 2,400
Yield 2024 *
-
Yield 2025 *
-
Free-Float 99.36%
More Fundamentals * Assessed data
Dynamic Chart
North American Morning Briefing : Stocks Edge -2- DJ
Tandem Diabetes Care Shares Rise After Stifel Upgrade MT
Stifel Upgrades Tandem Diabetes Care to Buy From Hold, Adjusts Price Target to $37 From $24 MT
Citigroup Raises Price Target on Tandem Diabetes Care to $31 From $25, Keeps Neutral Rating MT
Transcript : Tandem Diabetes Care, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 03:35 PM
Transcript : Tandem Diabetes Care, Inc. Presents at Oppenheimer 34th Annual Healthcare MedTech & Services Conference 2024, Mar-12-2024 01:20 PM
Transcript : Tandem Diabetes Care, Inc. Presents at 45th Annual Raymond James Institutional Investors Conference 2024, Mar-06-2024 11:00 AM
Tandem Diabetes Care Shares Drop 12% After Private Placement for Senior Notes DJ
Sector Update: Health Care Stocks Steady Pre-Bell Tuesday MT
Tandem Diabetes Care Plans $250 Million Private Placement Notes -- Shares Decline After Hours MT
Transcript : Tandem Diabetes Care, Inc. Presents at TD Cowen 44th Annual Health Care Conference 2024, Mar-04-2024 01:30 PM
Transcript : Tandem Diabetes Care, Inc. Presents at Citi?s 2024 Unplugged Medtech and Life Sciences Access Day, Feb-29-2024 01:00 PM
Earnings Flash (TNDM) TANDEM DIABETES CARE Reports Q4 Revenue $196.8M, vs. Street Est of $202.8M MT
Tandem Diabetes Care, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Transcript : Tandem Diabetes Care, Inc., Q4 2023 Earnings Call, Feb 21, 2024
More news
1 day+4.73%
1 week+8.75%
Current month+32.56%
1 month+29.11%
3 months+14.17%
6 months+69.63%
Current year+19.34%
More quotes
1 week
29.90
Extreme 29.9
35.52
1 month
25.78
Extreme 25.78
35.52
Current year
21.85
Extreme 21.85
35.52
1 year
13.82
Extreme 13.82
43.52
3 years
13.82
Extreme 13.82
155.86
5 years
13.82
Extreme 13.82
155.86
10 years
2.14
Extreme 2.14
226.40
More quotes
Managers TitleAgeSince
Chief Executive Officer 68 13-02-28
Director of Finance/CFO 51 13-08-31
Compliance Officer 58 21-12-31
Members of the board TitleAgeSince
Chairman 64 19-01-02
Director/Board Member 64 13-06-30
Director/Board Member 71 07-08-31
More insiders
Date Price Change Volume
24-03-27 35.3 +4.78% 2,204,784
24-03-26 33.69 +11.93% 2,669,482
24-03-25 30.1 -0.53% 1,292,883
24-03-22 30.26 -5.02% 943,776
24-03-21 31.86 -1.85% 1,757,736

Delayed Quote Nasdaq, March 27, 2024 at 04:00 pm EDT

More quotes
Tandem Diabetes Care, Inc. is a medical device company. The Company is focused on the design, development, and commercialization of technology solutions for people living with diabetes. It manufactures and sells the t:slim X2 insulin pump with Control-IQ technology. Its manufacturing, sales, and support activities principally focus on its flagship pump platform, the t:slim X2, and its complementary product offerings. Its t:slim X2 is based on the Company's technology platform and is the smallest durable insulin pump available in the United States. The Company has commercially offered two different automated insulin dosing (AID) algorithms on t:slim X2, including Control-IQ technology, which is an advanced hybrid-closed loop feature, designed to help increase a user's time in their targeted glycemic range. It was cleared by the Food and Drug Administration (FDA) to deliver automatic correction boluses in addition to adjusting insulin to help prevent high and low blood sugar.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
35.3 USD
Average target price
33.93 USD
Spread / Average Target
-3.87%
Consensus
  1. Stock
  2. Equities
  3. Stock Tandem Diabetes Care, Inc. - Nasdaq